AOP Orphan Pharmaceuticals AG Vienna Austria

Cherkasy Regional Oncology Centre Regional Treatment and Diagnostics Haematology Centre Department of Hematology Cherkasy Ukraine

Department of Hematology Zealand University Hospital Roskilde University of Copenhagen Denmark

Department of Laboratory Medicine Medical University of Vienna Vienna Austria and CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria

Kaposi MorCounty Teaching Hospital Department of Internal Medicine 2 Kaposvar Hungary

Medical University Vienna Department of Internal Medicine 1 Division of Haematology and Blood Coagulation Vienna Austria

Multiprofile Hospital for Active Treatment HristoBotev 1st Department of Internal Medicine Vratsa Bulgaria

Multiprofile Hospital for Active Treatment Sveta Marina Clinical Hematology Clinic Varna Bulgaria

Samara Kalinin Regional Clinical Hospital Samara Russia

Université de Paris CIC 1427 Inserm Paris France and Centre d'Investigations Cliniques AP HP Hospital Saint Louis Paris France

University Hospital Brno Clinic of Internal Medicine Hematology and Oncology Brno Czech Republic

University Hospital Hradec Kralove Department of Clinical Hematology Hradec Kralove Czech Republic

University Hospital in Krakow Teaching Unit of the Hematology Department Krakow Poland

University Multiprofile Hospital for Active Treatment Sveti Georgi Clinic of Hematology Medical University of Plovdiv Plovdiv Bulgaria

University of Debrecen Faculty of Medicine Department of Hematology Debrecen Hungary

Yaroslavl Regional Clinical Hospital Department of Hematology Yaroslavl Russia

Zobrazit více v PubMed

Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019;10:1–13. PubMed PMC

Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–1069. PubMed PMC

Mesa RA, Jamieson C, Bhatia R, et al. NCCN guidelines insights: myeloproliferative neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017;15:1193–1207. PubMed

Hasselbalch HC, Holmstrom MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41:5–19. PubMed PMC

Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018;8:3. PubMed PMC

Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037–2040. PubMed

Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418–5424. PubMed PMC

Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood. 2013;122:893–901. PubMed PMC

Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. Ann Hematol. 2015;94:901–910. PubMed PMC

Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon Alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV); a randomised, non-inferiority, phase III trial and its extension trial. Lancet Haematol. 2020;7:e196–e208. PubMed

Verger E, Soret-Dulphy J, Maslah N, et al. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8:94. PubMed PMC

Knudsen TA, Hansen DL, Ocias LF, et al. Three-year analysis of the DALIAH trial - a randomized controlled phase III clinical trial comparing recombinant interferon alpha-2 vs. hydroxyurea in patients with myeloproliferative neoplasms. Presented at: European Hematology Association 24th Annual Congress; June 13-16, 2019: Amsterdam, Netherlands. Abstract S1609.

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762–1769. PubMed PMC

Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–4833. PubMed

Turecek PL, Bossard MJ, Schoetens F, et al. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105:460–475. PubMed